Interestingly, local administration of the selective CB2 agonist—JWH133—or silencing CB2R expression induced a considerable regression of glioma by inducing glioma cell death (12, 38) and depressing the production of vascular endothelial growth factor (VEGF) in glioma cells (13). This evidence concerns the gene VEGFA and glioma.